Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 131
Filtrer
1.
Nat Commun ; 11(1): 4798, 2020 09 23.
Article de Anglais | MEDLINE | ID: mdl-32968066

RÉSUMÉ

Myeloid cells are known mediators of hypertension, but their role in initiating renin-induced hypertension has not been studied. Vitamin D deficiency causes pro-inflammatory macrophage infiltration in metabolic tissues and is linked to renin-mediated hypertension. We tested the hypothesis that impaired vitamin D signaling in macrophages causes hypertension using conditional knockout of the myeloid vitamin D receptor in mice (KODMAC). These mice develop renin-dependent hypertension due to macrophage infiltration of the vasculature and direct activation of renal juxtaglomerular (JG) cell renin production. Induction of endoplasmic reticulum stress in knockout macrophages increases miR-106b-5p secretion, which stimulates JG cell renin production via repression of transcription factors E2f1 and Pde3b. Moreover, in wild-type recipient mice of KODMAC/miR106b-/- bone marrow, knockout of miR-106b-5p prevents the hypertension and JG cell renin production induced by KODMAC macrophages, suggesting myeloid-specific, miR-106b-5p-dependent effects. These findings confirm macrophage miR-106b-5p secretion from impaired vitamin D receptor signaling causes inflammation-induced hypertension.


Sujet(s)
Hypertension rénale/métabolisme , Hypertension artérielle/métabolisme , Macrophages/métabolisme , microARN/métabolisme , Néphrite/métabolisme , Rénine/métabolisme , Animaux , Moelle osseuse , Transplantation de moelle osseuse , Modèles animaux de maladie humaine , Facteur de transcription E2F1/métabolisme , Stress du réticulum endoplasmique , Femelle , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Cellules myéloïdes , Récepteur calcitriol , Vitamine D
2.
Cancer Biol Ther ; 18(12): 917-926, 2017 Dec 02.
Article de Anglais | MEDLINE | ID: mdl-29020502

RÉSUMÉ

Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent. Key to the success of this multimodal approach is maintaining apoptotic sensitivity of tumour cells to the alkylating agent. This initial treatment likely establishes conditions contributing to development of drug resistance as alkylating agents form the O6-methylguanine adduct. This activates the mismatch repair (MMR) process inducing apoptosis and mutagenesis. This review describes key juxtaposed drivers in the balance between alkylation induced mutagenesis and apoptosis. Mutations in MMR genes are the probable drivers for alkylation based drug resistance. Critical to this interaction are the dose-response and temporal interactions between adduct formation and MMR mutations. The precision in dose interval, dose-responses and temporal relationships dictate a role for alkylating agents in either promoting experimental tumour formation or inducing tumour cell death with chemotherapy. Importantly, this resultant loss of chemotherapeutic selective pressure provides opportunity to explore novel therapeutics and appropriate combinations to minimise alkylation based drug resistance and tumour relapse.


Sujet(s)
Adduits à l'ADN/génétique , Résistance aux médicaments antinéoplasiques/génétique , Glioblastome/traitement médicamenteux , Récidive tumorale locale/traitement médicamenteux , Antinéoplasiques alcoylants/effets indésirables , Antinéoplasiques alcoylants/usage thérapeutique , Apoptose/génétique , Réparation de mésappariement de l'ADN/génétique , Réparation de l'ADN/génétique , Glioblastome/génétique , Glioblastome/anatomopathologie , Guanine/analogues et dérivés , Guanine/métabolisme , Humains , Mutation/génétique , Récidive tumorale locale/génétique , Récidive tumorale locale/anatomopathologie
3.
J Neurosurg Spine ; 27(4): 397-402, 2017 Oct.
Article de Anglais | MEDLINE | ID: mdl-28753065

RÉSUMÉ

OBJECTIVE Patient-reported outcomes (PROs) such as the Oswestry Disability Index (ODI) and EuroQol-5D (EQ-5D) are widely used to evaluate treatment outcomes following spine surgery for degenerative conditions. The goal of this study was to use the Charlson Comorbidity Index (CCMI) as a measure of general health status, for comparison with standard PROs. METHODS The authors examined serial CCMI scores, complications, and PROs in 371 patients treated surgically for degenerative lumbar spine conditions who were enrolled in the Quality and Outcomes Database from a single center. The cohort included 152 males (41%) with a mean age of 58.7 years. Patients with no, minor, or major complications were compared at baseline and at 1 year postoperatively. RESULTS Minor complications were observed in 177 patients (48%), and major complications in 34 (9%). There were no significant differences in preoperative ODI, EQ-5D, or CCMI among the 3 groups. At 1 year, there was a significantly greater deterioration in CCMI in the major complication group (1.03) compared with the minor (0.66) and no complication groups (0.44, p < 0.006), but no significant difference in ODI or EQ-5D. CONCLUSIONS Despite equivalent improvements in PROs, patients with major complications actually had greater deterioration in their general health status, as evidenced by worse CCMI scores. Because CCMI is predictive of medical and surgical risk, patients who sustained a major complication now carry a greater likelihood of adverse outcomes with future interventions, including subsequent spine surgery. Although PRO scores are a key metric, they fail to adequately reflect the potential long-term impact of major perioperative complications.


Sujet(s)
Dégénérescence de disque intervertébral/psychologie , Dégénérescence de disque intervertébral/chirurgie , Vertèbres lombales/chirurgie , Mesures des résultats rapportés par les patients , Complications postopératoires/diagnostic , Complications postopératoires/psychologie , Comorbidité , Femelle , Études de suivi , Humains , Dégénérescence de disque intervertébral/complications , Dégénérescence de disque intervertébral/diagnostic , Mâle , Adulte d'âge moyen , Qualité de vie , Indice de gravité de la maladie
4.
Nature ; 506(7489): 445-50, 2014 Feb 27.
Article de Anglais | MEDLINE | ID: mdl-24553142

RÉSUMÉ

Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain. Current standard therapy comprises surgery and radiation, but not cytotoxic chemotherapy as it does not further increase survival. Whole-genome and whole-exome sequencing of 47 hindbrain ependymomas reveals an extremely low mutation rate, and zero significant recurrent somatic single nucleotide variants. Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype. Transcriptional silencing driven by CpG methylation converges exclusively on targets of the Polycomb repressive complex 2 which represses expression of differentiation genes through trimethylation of H3K27. CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo. We conclude that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.


Sujet(s)
Ilots CpG/génétique , Épendymome/génétique , Épigenèse génétique/génétique , Animaux , Tumeurs du cerveau/traitement médicamenteux , Tumeurs du cerveau/génétique , Méthylation de l'ADN/effets des médicaments et des substances chimiques , Cellules souches embryonnaires/métabolisme , Épendymome/traitement médicamenteux , Épigénomique , Femelle , Régulation de l'expression des gènes tumoraux , Extinction de l'expression des gènes/effets des médicaments et des substances chimiques , Histone/effets des médicaments et des substances chimiques , Histone/métabolisme , Humains , Nourrisson , Souris , Souris de lignée NOD , Souris SCID , Mutation/génétique , Phénotype , Complexe répresseur Polycomb-2/métabolisme , Pronostic , Rhombencéphale/anatomopathologie , Tests d'activité antitumorale sur modèle de xénogreffe
5.
Mol Psychiatry ; 19(4): 519-26, 2014 Apr.
Article de Anglais | MEDLINE | ID: mdl-23628985

RÉSUMÉ

Dementia is a global epidemic with Alzheimer's disease (AD) being the leading cause. Early identification of patients at risk of developing AD is now becoming an international priority. Neocortical Aß (extracellular ß-amyloid) burden (NAB), as assessed by positron emission tomography (PET), represents one such marker for early identification. These scans are expensive and are not widely available, thus, there is a need for cheaper and more widely accessible alternatives. Addressing this need, a blood biomarker-based signature having efficacy for the prediction of NAB and which can be easily adapted for population screening is described. Blood data (176 analytes measured in plasma) and Pittsburgh Compound B (PiB)-PET measurements from 273 participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were utilised. Univariate analysis was conducted to assess the difference of plasma measures between high and low NAB groups, and cross-validated machine-learning models were generated for predicting NAB. These models were applied to 817 non-imaged AIBL subjects and 82 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) for validation. Five analytes showed significant difference between subjects with high compared to low NAB. A machine-learning model (based on nine markers) achieved sensitivity and specificity of 80 and 82%, respectively, for predicting NAB. Validation using the ADNI cohort yielded similar results (sensitivity 79% and specificity 76%). These results show that a panel of blood-based biomarkers is able to accurately predict NAB, supporting the hypothesis for a relationship between a blood-based signature and Aß accumulation, therefore, providing a platform for developing a population-based screen.


Sujet(s)
Maladie d'Alzheimer/sang , Maladie d'Alzheimer/anatomopathologie , Peptides bêta-amyloïdes/métabolisme , Néocortex/métabolisme , Sujet âgé , Sujet âgé de 80 ans ou plus , Maladie d'Alzheimer/génétique , Dérivés de l'aniline , Apolipoprotéines E/génétique , Chimiokine CCL3/sang , Études de cohortes , Cullines , Femelle , Humains , Interleukine-17 , Mâle , Néocortex/imagerie diagnostique , Polypeptide pancréatique , Tomographie par émission de positons , Valeur prédictive des tests , Courbe ROC , Thiazoles
6.
Transl Psychiatry ; 2: e164, 2012 Oct 02.
Article de Anglais | MEDLINE | ID: mdl-23032941

RÉSUMÉ

The Mediterranean diet (MeDi), due to its correlation with a low morbidity and mortality for many chronic diseases, has been widely recognised as a healthy eating model. We aimed to investigate, in a cross-sectional study, the association between adherence to a MeDi and risk for Alzheimer's disease (AD) and mild cognitive impairment (MCI) in a large, elderly, Australian cohort. Subjects in the Australian Imaging, Biomarkers and Lifestyle Study of Ageing cohort (723 healthy controls (HC), 98 MCI and 149 AD participants) completed the Cancer Council of Victoria Food Frequency Questionnaire. Adherence to the MeDi (0- to 9-point scale with higher scores indicating higher adherence) was the main predictor of AD and MCI status in multinominal logistic regression models that were adjusted for cohort age, sex, country of birth, education, apolipoprotein E genotype, total caloric intake, current smoking status, body mass index, history of diabetes, hypertension, angina, heart attack and stroke. There was a significant difference in adherence to the MeDi between HC and AD subjects (P < 0.001), and in adherence between HC and MCI subjects (P < 0.05). MeDi is associated with change in Mini-Mental State Examination score over an 18-month time period (P < 0.05) in HCs. We conclude that in this Australian cohort, AD and MCI participants had a lower adherence to the MeDi than HC participants.


Sujet(s)
Maladie d'Alzheimer/épidémiologie , Régime méditerranéen/statistiques et données numériques , Observance par le patient/statistiques et données numériques , Sujet âgé , Maladie d'Alzheimer/prévention et contrôle , Australie/épidémiologie , Dysfonctionnement cognitif/épidémiologie , Dysfonctionnement cognitif/prévention et contrôle , Études de cohortes , Études transversales , Femelle , Études de suivi , Évaluation gériatrique/méthodes , Évaluation gériatrique/statistiques et données numériques , Humains , Mâle , Tests neuropsychologiques/statistiques et données numériques , Facteurs de risque , Enquêtes et questionnaires
7.
Palliat Med ; 22(6): 711-7, 2008 Sep.
Article de Anglais | MEDLINE | ID: mdl-18715969

RÉSUMÉ

The aim of this study was to develop a new prognostic indicator to help predict survival in advanced cancer patients more accurately. Data on 329 patients obtained from a multi-centre study in London were analysed. A multifactorial Cox regression model was applied and validated using bootstrapping techniques. Predictive scores were calculated and used to produce a new prognostic index. The value of the index in predicting 14-day survival was then assessed. Four variables were found to be associated with worse survival: primary lung cancer, secondary liver cancer, raised C-Reactive protein and poor performance status (ECOG 4). Survival curves showed that patients designated as 'high' risk by the resulting index had significantly shorter survival than those designated as 'low' risk. A high score on the newly derived prognostic index is associated with poorer survival, but its clinical utility is limited by the relatively low predictive probability of the score.


Sujet(s)
Tumeurs/mortalité , Soins palliatifs , Malades en phase terminale , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Espérance de vie , Londres , Mâle , Adulte d'âge moyen , Tumeurs/diagnostic , Pronostic , Modèles des risques proportionnels , Analyse de survie , Jeune adulte
9.
Osteoarthritis Cartilage ; 15(10): 1190-8, 2007 Oct.
Article de Anglais | MEDLINE | ID: mdl-17500014

RÉSUMÉ

OBJECTIVE: The objective of this study was to characterize the rat monosodium iodoacetate (MIA)-induced model for osteoarthritis (OA) and determine the translatability of this model to human disease. This was accomplished through pathway, network and system level comparisons of transcriptional profiles generated from animal and human disease cartilage. METHODS: An OA phenotype was induced in rat femorotibial joints following a single injection of 200mug MIA per knee joint for a period of 2 or 4 weeks. Lesion formation in the rat joints was confirmed by histology. Gene expression changes were measured using the Agilent rat whole genome microarrays. Cartilage was harvested from human knees and gene expression changes were measured using the Agilent human arrays. RESULTS: One thousand nine hundred and forty-three oligos were differentially expressed in the MIA model, of these, approximately two-thirds were up-regulated. In contrast, of the 2130 differentially expressed oligos in human disease tissue, approximately two-thirds were down-regulated. This dramatic difference was observed throughout each level of the comparison. The total overlap of genes modulated in the same direction between rat and human was less than 4%. Matrix degradation and inflammatory genes were differentially regulated to a much greater extent in MIA than human disease tissue. CONCLUSION: This study demonstrated, through multiple levels of analysis, that little transcriptional similarity exists between rat MIA and human OA derived cartilage. As disease modulatory activities for potential therapeutic agents often do not translate from animal models to human disease, this and like studies may provide a basis for understanding the discrepancies.


Sujet(s)
Arthrite expérimentale/génétique , Cartilage articulaire/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Arthrose/induit chimiquement , Facteurs de transcription/analyse , Transcription génétique/effets des médicaments et des substances chimiques , Animaux , Arthrite expérimentale/induit chimiquement , Arthrite expérimentale/anatomopathologie , Cartilage articulaire/anatomopathologie , Modèles animaux de maladie humaine , Humains , Iodo-acétates/administration et posologie , Iodo-acétates/toxicité , Mâle , Arthrose/génétique , Arthrose/anatomopathologie , Rats , Rat Wistar , RT-PCR/méthodes , Statistiques comme sujet
10.
Biol Lett ; 2(1): 88-91, 2006 Mar 22.
Article de Anglais | MEDLINE | ID: mdl-17148334

RÉSUMÉ

Marine organisms have evolved defence mechanisms to prevent epibiosis. This study investigated the anti-settlement properties of natural periostracal microtopographies of two mytilid species, Mytilus edulis (from North, Baltic and White Seas) and Perna perna (from the SW Atlantic). Resin replicas of shells were exposed to cyprids of the barnacle Semibalanus balanoides. Replicas with intact isotropic microtopographies and smooth controls were much less fouled than roughened anisotropic surfaces. This indicates that in both M. edulis and P. perna the periostracum possesses a generic anti-settlement property, at least against S. balanoides cyprids, which is not regionally adapted. Such a potential globally effective anti-settlement mechanism possibly contributes to the invasive success of Mytilidae.


Sujet(s)
Mytilus edulis/croissance et développement , Perna/croissance et développement , Animaux , Mytilus edulis/ultrastructure , Perna/ultrastructure , Dynamique des populations , Thoracica/physiologie
11.
Dev Med Child Neurol ; 48(9): 756-60, 2006 Sep.
Article de Anglais | MEDLINE | ID: mdl-16904023

RÉSUMÉ

Pyruvate dehydrogenase (PDH) deficiency is a major cause of neurological dysfunction and lactic acidosis in infancy and early childhood. The great majority of cases (>80%) result from mutations in the X-linked gene for the E1alpha subunit of the complex (PDHA1). Mutations in the genes for the other subunits have all been described, but only dihydrolipoamide dehydrogenase (E3) and E3 binding protein (E3BP) defects contribute significantly to the total number of patients with PDH deficiency. Although previously considered rare, with only 13 reported cases, we have found that mutations in PDX1, the gene for the E3 binding protein, are in fact relatively common. Clinical, biochemical, and genetic features of six new patients (four males, two females; age range 15mo-6y) with mutations in this gene are compared with previously reported cases. All patients with E3BP deficiency identified to date have mutations which completely prevent synthesis of the protein product. However, they are generally less severely affected than patients with PDHA1 mutations, although there is considerable overlap in clinical and neuroradiological features.


Sujet(s)
Déficit en complexe pyruvate-déshydrogénase/génétique , Complexe du pyruvate déshydrogénase/génétique , Enfant , Enfant d'âge préscolaire , Analyse de mutations d'ADN , Femelle , Humains , Nourrisson , Mâle , Sous-unités de protéines/déficit , Sous-unités de protéines/génétique , Complexe du pyruvate déshydrogénase/métabolisme , Déficit en complexe pyruvate-déshydrogénase/diagnostic , Déficit en complexe pyruvate-déshydrogénase/métabolisme , Indice de gravité de la maladie
12.
Dev Med Child Neurol ; 46(10): 710-2, 2004 Oct.
Article de Anglais | MEDLINE | ID: mdl-15473177

RÉSUMÉ

Two individuals with pyruvate dehydrogenase (PDH) deficiency due to missense mutations in the gene for the E1alpha subunit (PDHA1) presented during childhood with dystonia. The first patient, a male, presented at age 4 years with dystonia affecting the lower limbs, which responded to treatment with combined carbidopa and levodopa. The second patient, a female, was first investigated at age 6 years because of a dystonic gait disorder. In both patients, the main clue to the biochemical diagnosis was a raised concentration of lactate in the cerebrospinal fluid. PDH activity was significantly reduced in cultured fibroblasts in both cases. Dystonia is a previously unrecognized major manifestation of PDH deficiency and is of particular interest as the mutations in the PDHA1 gene in these patients have both been identified previously in individuals with typical presentations of the condition.


Sujet(s)
Troubles dystoniques/diagnostic , Troubles dystoniques/étiologie , Déficit en complexe pyruvate-déshydrogénase/complications , Déficit en complexe pyruvate-déshydrogénase/diagnostic , Enfant , Enfant d'âge préscolaire , Troubles dystoniques/génétique , Femelle , Humains , Mâle , Mutation faux-sens , Pyruvate dehydrogenase (lipoamide)/génétique , Déficit en complexe pyruvate-déshydrogénase/génétique
13.
J Inherit Metab Dis ; 27(4): 477-85, 2004.
Article de Anglais | MEDLINE | ID: mdl-15303005

RÉSUMÉ

Pyruvate dehydrogenase deficiency is an important cause of primary lactic acidosis. Most cases occur as a result of mutations in the gene for the E1 alpha subunit of the complex, with a small number resulting from mutations in genes for other components, most commonly the E3 and E3-binding protein subunits. We describe pyruvate dehydrogenase E3-binding protein deficiency in two siblings in each of two unrelated families from Kuwait. The index patient in each family had reduced pyruvate dehydrogenase activity in cultured fibroblasts and no detectable immunoreactive E3-binding protein. Both were homozygous for nonsense mutations in the E3-binding protein gene, one involving the codon for glutamine 266, the other the codon for tryptophan 5.


Sujet(s)
Acidose lactique/enzymologie , Peptides/déficit , Séquence nucléotidique , Cellules cultivées , Codon/génétique , Codon non-sens , Consanguinité , ADN complémentaire/composition chimique , Femelle , Fibroblastes/enzymologie , Glutamine/génétique , Homozygote , Humains , Nourrisson , Nouveau-né , Koweït , Imagerie par résonance magnétique , Peptides/génétique , Complexe du pyruvate déshydrogénase/génétique , Syrie/ethnologie , Tryptophane/génétique
14.
J Ethnopharmacol ; 92(2-3): 311-6, 2004 Jun.
Article de Anglais | MEDLINE | ID: mdl-15138017

RÉSUMÉ

In this study, the vasodilatory actions of nine edible tropical plant extracts were investigated. Ipomoea batatas (sweet potato leaf), Piper betle (betel leaf), Anacardium occidentale (cashew leaf), Gynandropsis gynandra (maman leaf), Carica papaya (papaya leaf), and Mentha arvensis (mint leaf) extracts exhibited more than 50% relaxing effect on aortic ring preparations, while Piper betle and Cymbopogon citratus (lemongrass stalk) showed comparable vasorelaxation on isolated perfused mesenteric artery preparation. The vascular effect on the aortic ring preparations were mainly endothelium-dependent, and mediated by nitric oxide (NO) as supported by the inhibition of action in the presence of N(omega)-nitro-L-arginine (NOLA), an nitric oxide synthase (NOS) inhibitor, or by the removal of endothelium. In contrast, vasodilatory actions in resistance vessels (perfused mesenteric vascular beds) appear to involve several biochemical mediators, including NO, prostanoids, and endothelium-dependent hyperpolarizing factors (EDHFs). Total phenolic contents and antioxidant capacities varied among different extracts and found to be independent of vascular relaxation effects. This study demonstrates that many edible plants common in Asian diets to possess potential health benefits, affording protection at the vascular endothelium level.


Sujet(s)
Aorte thoracique/effets des médicaments et des substances chimiques , Artères mésentériques/effets des médicaments et des substances chimiques , Plantes comestibles/composition chimique , Plantes médicinales/composition chimique , Vasodilatation/effets des médicaments et des substances chimiques , Vasodilatateurs/pharmacologie , Animaux , Techniques in vitro , Malaisie , Extraits de plantes/isolement et purification , Extraits de plantes/pharmacologie , Rats , Rats de lignée WKY , Climat tropical , Vasodilatateurs/isolement et purification
15.
J Inherit Metab Dis ; 27(1): 57-65, 2004.
Article de Anglais | MEDLINE | ID: mdl-14970746

RÉSUMÉ

In three unrelated patients with systemic cytochrome oxidase deficiency resulting from mutations in the SURF1 gene, the same mutation in the splice donor site of intron 3 was identified. All three patients were compound heterozygotes, two for the common insertion/deletion mutation in exon 4. In all three cases, complete definition of the causative mutations was only resolved by combined analysis of cDNA and genomic DNA. Several factors were identified that contributed to the diagnostic difficulties: preferential amplification of deleted cDNA, significant formation of heteroduplexes in cDNA PCR amplification and unequal representation of heterozygous peaks in genomic DNA sequences. These patients emphasize the need to perform mutation analysis on both cDNA and genomic DNA wherever possible.


Sujet(s)
Déficit en cytochrome-c oxydase/diagnostic , Déficit en cytochrome-c oxydase/génétique , Maladie de Leigh/diagnostic , Maladie de Leigh/génétique , Mutation , Protéines/génétique , Épissage alternatif , Séquence nucléotidique , Cellules cultivées , Analyse de mutations d'ADN , Éléments transposables d'ADN , ADN complémentaire , Diagnostic différentiel , Exons , Amplification de gène , Délétion de gène , Hétérozygote , Humains , Introns , Protéines membranaires , Protéines mitochondriales , Données de séquences moléculaires , Hétéroduplexes d'acides nucléiques , Réaction de polymérisation en chaîne , Sites d'épissage d'ARN
16.
Hum Mutat ; 22(6): 496-7, 2003 Dec.
Article de Anglais | MEDLINE | ID: mdl-14635113

RÉSUMÉ

In a patient with fatal neonatal lactic acidosis due to pyruvate dehydrogenase deficiency, the only potential mutation detected was c.888C>G in PDHA1, the gene for the E1alpha subunit of the complex. This would result in a substitution of glutamate for aspartate (D296E). Pathogenicity of this minor alteration in amino acid sequence was demonstrated by expression studies. By comparing the mutant sequence with the known structures of the E1 components of pyruvate dehydrogenase and the closely related branched chain alpha-ketoacid dehydrogenase, an explanation for the profound consequences of the mutation can be proposed.


Sujet(s)
Substitution d'acide aminé/génétique , Pyruvate dehydrogenase (lipoamide)/génétique , Déficit en complexe pyruvate-déshydrogénase/génétique , Acide aspartique/génétique , Domaine catalytique/génétique , Analyse de mutations d'ADN , ADN complémentaire/composition chimique , ADN complémentaire/génétique , Issue fatale , Femelle , Fibroblastes/enzymologie , Fibroblastes/métabolisme , Acide glutamique/génétique , Humains , Nouveau-né , Mâle , Modèles moléculaires , Mutation , Pyruvate dehydrogenase (lipoamide)/composition chimique , Pyruvate dehydrogenase (lipoamide)/métabolisme , Déficit en complexe pyruvate-déshydrogénase/anatomopathologie
17.
Cardiovasc Res ; 52(3): 361-71, 2001 Dec.
Article de Anglais | MEDLINE | ID: mdl-11738053

RÉSUMÉ

The cardiovascular health benefits of longchain n-3 polyunsaturated fatty acids (PUFAs) have been reported to exert at several different cellular control mechanisms. These include, effects on lipoprotein metabolism, haemostatic function, platelet/vessel wall interactions, anti-arrhythmic actions and also inhibition of proliferation of smooth muscle cells and therefore growth of the atherosclerotic plaque. Fish oil feeding has also been found to result in moderate reductions in blood pressure and to modify vascular neuroeffector mechanisms. The majority of such cardiovascular benefits of n-3 PUFAs are likely to be mediated in the vascular wall and at the vascular endothelium level, since this monolayer of cells plays a central role in the regulation and maintenance of cardiovascular homeostasis and function. While these processes include endothelium-derived vasorelaxant and vasoconstrictor compounds, the vascular endothelium also plays host to many receptors, binding proteins, transporters and signalling mechanisms. Accordingly, endothelial dysfunction, which underlies many cardiovascular disease conditions, can trigger acute vascular events including vasospasm, thrombosis or restenosis leading to ischaemia. The longchain n-3 PUFAs have been reported to possess several properties that may positively influence vascular function. These include favourable mediator profiles (nitric oxide, eicosanoids) that influence vascular reactivity, change in vascular tone via actions on selective ion channels, and maintenance of vascular integrity. In addition to direct effects on contractility, n-3 PUFAs may affect vascular function, and the process of atherogenesis, via inhibition of vascular smooth muscle cell proliferation at the gene expression level, and by modifying expression of inflammatory cytokinesis and adhesion molecules. Collectively, these properties are consistent with pleiotropic actions of longchain n-3 PUFAs, and may explain the beneficial cardiovascular protection of this family of fatty acids that have been clearly evident through epidemiological data as well from more recent large-scale clinical trials.


Sujet(s)
Maladies cardiovasculaires/physiopathologie , Vaisseaux coronaires/physiopathologie , Acides gras omega-3/pharmacologie , Vasoconstriction/effets des médicaments et des substances chimiques , Antiarythmiques , Artériosclérose/traitement médicamenteux , Artériosclérose/métabolisme , Maladies cardiovasculaires/traitement médicamenteux , Maladies cardiovasculaires/métabolisme , Molécules d'adhérence cellulaire/métabolisme , Division cellulaire , Vaisseaux coronaires/effets des médicaments et des substances chimiques , Cytokines/métabolisme , Éicosanoïdes/métabolisme , Endothélium vasculaire/effets des médicaments et des substances chimiques , Endothélium vasculaire/métabolisme , Prostacycline/métabolisme , Acides gras omega-3/métabolisme , Acides gras omega-3/usage thérapeutique , Fibrinolytiques , Humains , Canaux ioniques/effets des médicaments et des substances chimiques , Canaux ioniques/métabolisme , Leucocytes/anatomopathologie , Contraction myocardique/effets des médicaments et des substances chimiques , Monoxyde d'azote/métabolisme
18.
Article de Anglais | MEDLINE | ID: mdl-11545625

RÉSUMÉ

Two currently available edible oils-olive and canola-and two oil blends of plant origin having different n-3/n-6 polyunsaturated fatty acid (PUFA) ratios were evaluated for their ability to modify vascular dysfunction in the spontaneously hypertensive rat (SHR). Synthetic diets supplemented with test oils (5% w/w) were fed for 12 weeks, and segments of thoracic aorta used to assess vascular function. Vessels from the SHR displayed a spontaneous constrictor response after the inhibition of endothelial cell nitric oxide (NO) with N(omega)-nitro-L-arginine (NOLA). Dietary alpha -linoleate enrichment led to a reduction (P<0.05) in this abnormality with a dietary n-3/n-6 PUFA ratio of 1.0 (blend-1) yielding the best outcome. Relaxation to acetylcholine (ACh) was unaffected by dietary lipid supplementation. NOLA treated rings also displayed contractions to ACh that were abolished by indomethacin, thromboxane antagonists SQ29548, picotamide and flavonoids kaempferol and quercetin. In contrast, alpha-tocopherol, rutin and the lipoxygenase inhibitor esculetin resulted in only partial (30-55%) inhibition, and were ineffective against the NOLA-induced contraction suggesting the operation of different biochemical mechanisms in mediating the spontaneous and Ach-induced contractions. Results implicate plant-based oils and antioxidants as potential modulators of vascular function.


Sujet(s)
Antioxydants/métabolisme , Régime alimentaire , Acides gras insaturés/métabolisme , Hypertension artérielle/prévention et contrôle , Kaempférols , Quercétine/analogues et dérivés , Acétylcholine/antagonistes et inhibiteurs , Acétylcholine/pharmacologie , Animaux , Antioxydants/pharmacologie , Aorte/métabolisme , Composés hétérocycliques bicycliques , Agents cardiovasculaires/pharmacologie , Relation dose-effet des médicaments , Endothélium vasculaire/métabolisme , Flavonoïdes/pharmacologie , Hydrazines/pharmacologie , Indométacine/pharmacologie , Métabolisme lipidique , Monoxyde d'azote/métabolisme , Acides phtaliques/pharmacologie , Huiles végétales/usage thérapeutique , Antiagrégants plaquettaires/pharmacologie , Quercétine/pharmacologie , Rats , Rats de lignée SHR , Rutoside/pharmacologie , Ombelliférones/pharmacologie , alpha-Tocophérol/pharmacologie
19.
J Pharmacol Toxicol Methods ; 45(1): 39-46, 2001.
Article de Anglais | MEDLINE | ID: mdl-11489663

RÉSUMÉ

A modified apparatus is described that provides for the simultaneous bathing of the serosa of an intact piece of isolated guinea pig ileum while allowing infusion of the isolated lumen. The comparative compartmental potency of the opioid agonists morphine, casomorphins, and enkephalins to inhibit electrically driven contractions are described in this system. The rank-order potency for serosally applied opioid agonists was (IC(50) values, nM): [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]-enkephalin (DAMGO) (15)>[D-Ala(2),D-Leu(5)]-enkephalin (DADLE) (35)> or =morphine (46)> or =[D-Ala(2)]-met-enkephalinamide (55)>[D-Ala(2)]-beta-casomorphin[1--4] amide (122)>beta-casomorphin[1--4] amide (940)>met- and leu-enkephalin (>6000). This contrasted to the rank-order potency for the luminally applied opioid agonists: DADLE (63)>DAMGO (135)>[D-Ala(2)]-met-enkephalinamide=morphine (4700)>[D-Ala(2)]-beta-casomorphin[1--4] amide (29000). beta-Casomorphin[1--4] amide, leu-enkephalin and met-enkephalin are mostly inactive when applied luminally. Furthermore, the opioid antagonists, casoxin 4 and [D-Ala(2)]-casoxin 4, when infused into the lumen, significantly overcame the inhibitory effect of morphine added to the serosal side. This model provides an assay and screening system to differentiate between the effects of chemical agents applied via the blood stream (serosa) or food side (lumen) on quiescent or electrically driven gut activity of the nervous plexi or receptor systems of the ileum.


Sujet(s)
Analgésiques morphiniques/pharmacologie , Endorphines/pharmacologie , Enképhalines/pharmacologie , Iléum/effets des médicaments et des substances chimiques , Morphine/pharmacologie , Muscles lisses/effets des médicaments et des substances chimiques , Antagonistes narcotiques/pharmacologie , Animaux , Stimulation électrique , Leucine-enképhaline/pharmacologie , Méthionine-enképhaline/pharmacologie , Études d'évaluation comme sujet , Femelle , Cochons d'Inde , Techniques in vitro , Pompes à perfusion , Concentration inhibitrice 50 , Mâle , Contraction musculaire/effets des médicaments et des substances chimiques , Récepteurs aux opioïdes/effets des médicaments et des substances chimiques
20.
Article de Anglais | MEDLINE | ID: mdl-11418024

RÉSUMÉ

Recent reports suggest modulation of chronic obstructive pulmonary disease by dietary polyunsaturated fatty acids. In the present study, we re-examined this possibility by using an established animal model of pulmonary sensitisation. Adult guinea pigs were fed diets supplemented (10% w/w) with either olive, canola or safflower oil for 4 weeks before sensitising with ovalbumin and continuing on various diets for a further 6 week period. Neither the contraction following ovalbumin challenge, nor the responses to histamine, carbachol and various eicosanoid mediators - prostaglandin F(2 alpha), leukotriene C(4), thromboxane mimetic U44619 - of isolated segments of airway tissue were altered (P>0.05, ANOVA) by the dietary lipid treatment. Lipid analysis showed changes in membrane linoleic acid (18:2n-6) and alpha -linolenic acids (alpha 18:3n-3) in lung phospholipids consistent with dietary intakes. However, no significant further desaturation/elongation of these dietary precursors was evident. Ovalbumin induced contraction was fully reversed by the lipoxygenase inhibitor esculetin whilst indomethacin resulted in a slight increase possibly due to the inhibition of bronchodilator prostanoids. Results confirm that under the conditions employed airway function was not influenced by the variable dietary intakes of n-3 and n-6 PUFA.


Sujet(s)
Bronches/effets des médicaments et des substances chimiques , Acide 15-hydroxy-11alpha,9alpha-(époxyméthano)prosta-5,13-diénoïque/pharmacologie , Analyse de variance , Animaux , Antioxydants/pharmacologie , Carbachol/pharmacologie , Agents cardiovasculaires/pharmacologie , Compléments alimentaires , Dinoprost/pharmacologie , Relation dose-effet des médicaments , Acides gras/métabolisme , Acides gras monoinsaturés/pharmacologie , Cochons d'Inde , Histamine/pharmacologie , Indométacine/pharmacologie , Leucotriène C4/pharmacologie , Acide linoléique/pharmacologie , Métabolisme lipidique , Poumon/métabolisme , Mâle , Huile d'olive , Ovalbumine/métabolisme , Ovalbumine/pharmacologie , Huiles végétales/pharmacologie , Huile de colza , Huile de carthame/pharmacologie , Thromboxanes/pharmacologie , Ombelliférones/pharmacologie , Vasoconstricteurs/pharmacologie , Acide alpha-linolénique/pharmacologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...